References: 24 Comments Thank you so much for talking about this
Another idea is adjusting benefits e.g., introducing a combined deductible for Parts A/B and uniform coinsurance to discourage overuse
Retatrutide, the triple agonist targeting GLP-1, GIP, and glucagon receptors, shows approximately 24% weight loss in phase 2 trials
But that hasn't stopped people from self-directed experimentation
Samea-Andabjadid S, Ghassemi-Golezani K, Nasrollahzadeh S, Najafi N
Peptides Lab UK supplies bacteriostatic water as a sterile, laboratory-grade reconstitution solvent specifically formatted for use with lyophilised research peptide preparations